Tycel Phillips

4.1k total citations
149 papers, 1.6k citations indexed

About

Tycel Phillips is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Tycel Phillips has authored 149 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Pathology and Forensic Medicine, 85 papers in Genetics and 71 papers in Oncology. Recurrent topics in Tycel Phillips's work include Lymphoma Diagnosis and Treatment (123 papers), Chronic Lymphocytic Leukemia Research (83 papers) and CAR-T cell therapy research (42 papers). Tycel Phillips is often cited by papers focused on Lymphoma Diagnosis and Treatment (123 papers), Chronic Lymphocytic Leukemia Research (83 papers) and CAR-T cell therapy research (42 papers). Tycel Phillips collaborates with scholars based in United States, United Kingdom and France. Tycel Phillips's co-authors include Ryan A. Wilcox, Sumana Devata, Mark Kaminski, Moshe Talpaz, Philip S. Boonstra, Paul M. Barr, Vincent Ribrag, Javier Muñoz, Paula Bockenstedt and Samuel A. Merrill and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Tycel Phillips

139 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tycel Phillips United States	22	956	899	554	367	278	149	1.6k
Javier Muñoz United States	23	886 0.9×	1.2k 1.4×	545 1.0×	333 0.9×	154 0.6×	133	1.8k
Pau Abrisqueta Spain	22	1.0k 1.1×	636 0.7×	873 1.6×	421 1.1×	174 0.6×	124	1.8k
Timothy S. Fenske United States	27	1.2k 1.3×	1.7k 1.9×	624 1.1×	522 1.4×	543 2.0×	162	2.6k
Celeste Bello United States	13	808 0.8×	544 0.6×	640 1.2×	247 0.7×	250 0.9×	63	1.3k
Charles Herbaux France	23	1.2k 1.2×	675 0.8×	1.1k 2.0×	591 1.6×	460 1.7×	111	1.9k
Christian H. Geisler Denmark	25	1.8k 1.8×	1.1k 1.2×	1.2k 2.2×	512 1.4×	305 1.1×	52	2.4k
P. M. Kluin Netherlands	21	1.0k 1.1×	797 0.9×	431 0.8×	314 0.9×	260 0.9×	40	1.8k
Achiel Van Hoof Belgium	18	1.9k 2.0×	1.3k 1.5×	918 1.7×	339 0.9×	235 0.8×	33	2.6k
Carla Casulo United States	19	1.3k 1.4×	1.1k 1.2×	555 1.0×	400 1.1×	111 0.4×	95	1.9k
Enrico Derenzini Italy	25	1.2k 1.2×	766 0.9×	344 0.6×	370 1.0×	145 0.5×	99	1.9k

Countries citing papers authored by Tycel Phillips

Since Specialization

Citations

This map shows the geographic impact of Tycel Phillips's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tycel Phillips with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tycel Phillips more than expected).

Fields of papers citing papers by Tycel Phillips

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tycel Phillips. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tycel Phillips. The network helps show where Tycel Phillips may publish in the future.

Co-authorship network of co-authors of Tycel Phillips

This figure shows the co-authorship network connecting the top 25 collaborators of Tycel Phillips. A scholar is included among the top collaborators of Tycel Phillips based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tycel Phillips. Tycel Phillips is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Phillips, Tycel, et al.. (2025). The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL. Cancers. 17(7). 1192–1192. 2 indexed citations

Shouse, Geoffrey, Lu Chen, D. Lynne Smith, et al.. (2025). Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma. Leukemia & lymphoma. 66(14). 2790–2793.

Beaven, Anne, Susan M. Geyer, Jonathon B. Cohen, et al.. (2024). Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma. Blood. 144(Supplement 1). 1661.3–1661.3.

Karimi, Yasmin, Catherine Thiéblemont, Hervé Ghesquières, et al.. (2024). Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7039–7039. 5 indexed citations

Phillips, Tycel, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.. Journal of Clinical Oncology. 42(16_suppl). 7008–7008. 7 indexed citations

Weiss, J. & Tycel Phillips. (2024). Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma. Cancers. 16(9). 1724–1724. 3 indexed citations

Vose, Julie M., Chan Y. Cheah, Michael Roost Clausen, et al.. (2024). 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma. Blood. 144(Supplement 1). 4480–4480. 8 indexed citations

Liu, Tingting, Tycel Phillips, Geoffrey Shouse, et al.. (2023). T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia. Molecular Cancer Therapeutics. 22(9). 1040–1051. 8 indexed citations

Phillips, Tycel, et al.. (2023). Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial. Leukemia & lymphoma. 64(5). 1017–1025. 2 indexed citations

10.

Phillips, Tycel, Pieternella J. Lugtenburg, Anthony Wang, et al.. (2023). Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab. Clinical Lymphoma Myeloma & Leukemia. 24(3). e78–e87.e2. 2 indexed citations

11.

Hu, Nan, Fangyang Wang, Tianyu Sun, et al.. (2021). Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. Clinical Cancer Research. 27(8). 2301–2313. 19 indexed citations

12.

Assouline, Sarit, Amitkumar Mehta, Tycel Phillips, et al.. (2021). TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data. Blood. 138(Supplement 1). 2488–2488. 4 indexed citations

13.

Phillips, Tycel, Michael Dickinson, Franck Morschhauser, et al.. (2021). Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy. Blood. 138(Supplement 1). 130–130. 20 indexed citations

14.

Patel, Krish, Jean‐Marie Michot, Asher Chanan‐Khan, et al.. (2021). Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood. 138(Supplement 1). 2494–2494. 19 indexed citations

15.

Morschhauser, Franck, Carmelo Carlo‐Stella, Michael Dickinson, et al.. (2021). Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). Blood. 138(Supplement 1). 128–128. 20 indexed citations

16.

Phillips, Tycel, Adam J. Olszewski, Javier Muñoz, et al.. (2020). Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. Blood. 136(Supplement 1). 37–38. 37 indexed citations

17.

Gritti, Giuseppe, Paula Marlton, Tycel Phillips, et al.. (2020). Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study. Blood. 136(Supplement 1). 45–47. 16 indexed citations

18.

Kamdar, Manali, Hongli Li, Robert W. Chen, et al.. (2019). Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Advances. 3(20). 3132–3135. 15 indexed citations

19.

Ramchandren, Radhakrishnan, et al.. (2017). A Phase II Multicenter Single Arm Study of Ibrutinib in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma. Blood. 130. 1527–1527. 2 indexed citations

20.

Phillips, Tycel & R. R. Macdonald. (1971). Comparative Effect of Pethidine, Trichloroethylene, and Entonox on Fetal and Neonatal Acid-Base and Po ₂. BMJ. 3(5774). 558–560. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact